Tumour necrosis factor inhibitors (anti-TNF), including infliximab, etanercept, adalimumab, and golimumab, are widely used to treat immune-mediated diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis (PsO), and psoriatic arthritis (PsA). The gene discussed is TNF; the disease is psoriasis.